Burkitt and Burkitt-Like Lymphomas: a Systematic Review.


Journal

Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967

Informations de publication

Date de publication:
06 03 2020
Historique:
entrez: 8 3 2020
pubmed: 8 3 2020
medline: 13 7 2021
Statut: epublish

Résumé

Burkitt's lymphoma and its leukemic form (Burkitt cell acute lymphoblastic leukemia) are a highly aggressive disease. We review the classification, clinical presentation, histology, cytogenetics, and the treatment of the disease. Burkitt's lymphoma might be associated with tumor lysis syndrome which is a potentially fatal complication that occurs spontaneously or upon initiation of chemotherapy. Major improvements were made in the treatment of pediatric and adults population using short-course dose-intensive chemotherapy regimens, usually 1 week after a prephase induction. Addition of Rituximab to chemotherapy has become a standard of care. Relapsed/refractory disease has a very poor prognosis and the benefit from autologous/allogeneic hematopoietic stem cell transplant remains uncertain. Rituximab-based short-course dose-intensive chemotherapy is the standard of care of Burkitt's lymphoma even in the immunodeficiency-related form.

Identifiants

pubmed: 32144513
doi: 10.1007/s11912-020-0898-8
pii: 10.1007/s11912-020-0898-8
doi:

Substances chimiques

Antigens, CD20 0
BCL6 protein, human 0
Proto-Oncogene Proteins c-bcl-6 0
Rituximab 4F4X42SYQ6

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

33

Références

J Clin Oncol. 1995 Feb;13(2):359-72
pubmed: 7844597
Cancer. 1998 Feb 15;82(4):766-74
pubmed: 9477111
Br J Haematol. 2014 Nov;167(3):394-401
pubmed: 25066629
J Clin Oncol. 1991 Jan;9(1):123-32
pubmed: 1985161
J Clin Oncol. 1986 Dec;4(12):1732-9
pubmed: 3491184
Br J Haematol. 2006 Jun;133(6):634-7
pubmed: 16704438
Cancer. 2006 Apr 1;106(7):1569-80
pubmed: 16502413
Lancet. 2016 Jun 11;387(10036):2402-11
pubmed: 27080498
Curr Opin Oncol. 2002 Sep;14(5):528-32
pubmed: 12192272
Best Pract Res Clin Haematol. 2018 Sep;31(3):279-284
pubmed: 30213397
Lancet. 1991 Apr 6;337(8745):805-9
pubmed: 1672911
Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820
pubmed: 12852656
J Clin Oncol. 1998 Dec;16(12):3788-95
pubmed: 9850023
Biol Blood Marrow Transplant. 2013 Feb;19(2):173-9
pubmed: 23200705
Afr Health Sci. 2007 Sep;7(3):166-75
pubmed: 18052871
Ann Oncol. 1997;8 Suppl 2:101-4
pubmed: 9209651
J Clin Oncol. 1991 Jan;9(1):133-8
pubmed: 1985162
Blood. 2008 Sep 15;112(6):2248-60
pubmed: 18612102
Curr Hematol Malig Rep. 2015 Sep;10(3):266-71
pubmed: 26013028
Hematol Oncol Clin North Am. 2016 Dec;30(6):1333-1343
pubmed: 27888884
Br J Cancer. 1998 Jun;77(12):2281-5
pubmed: 9649146
Neurology. 1981 Oct;31(10):1277-81
pubmed: 6287347
Br J Surg. 1958 Nov;46(197):218-23
pubmed: 13628987
East Afr Med J. 2004 Aug;(8 Suppl):S68-77
pubmed: 15622605
Ann Oncol. 2002 Aug;13(8):1264-74
pubmed: 12181251
Pediatr Blood Cancer. 2009 Sep;53(3):366-70
pubmed: 19434731
Leukemia. 2005 Jun;19(6):945-52
pubmed: 15800666
Oncologist. 2006 Apr;11(4):375-83
pubmed: 16614233
Lancet. 2012 Mar 31;379(9822):1234-44
pubmed: 22333947
Leukemia. 2013 Apr;27(5):1174-7
pubmed: 22940833
Adolesc Health Med Ther. 2016 Dec 23;8:11-29
pubmed: 28096698
Hematology Am Soc Hematol Educ Program. 2009;:523-31
pubmed: 20008237
Cancer. 2002 Mar 1;94(5):1492-9
pubmed: 11920506
J Clin Oncol. 1986 Aug;4(8):1219-26
pubmed: 3525767
Blood. 2015 Jul 9;126(2):160-6
pubmed: 25957391
J Clin Oncol. 1996 Sep;14(9):2465-72
pubmed: 8823324
N Engl J Med. 2013 Nov 14;369(20):1915-25
pubmed: 24224624
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2014 Dec 18;124(26):3870-9
pubmed: 25359988
J Clin Oncol. 1999 Aug;17(8):2461-70
pubmed: 10561310
Cancer Invest. 2000;18(6):574-83
pubmed: 10923106
Blood. 2010 Nov 11;116(19):3724-34
pubmed: 20664057
Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46
pubmed: 2069232
Br J Haematol. 2012 Mar;156(6):744-56
pubmed: 22260300
Blood. 2001 Jun 1;97(11):3370-9
pubmed: 11369626
Blood. 2010 Dec 16;116(25):5600-4
pubmed: 20813897
Blood. 1999 Nov 15;94(10):3294-306
pubmed: 10552938
Ann Oncol. 2005 Dec;16(12):1928-35
pubmed: 16284057
Blood. 2007 Apr 1;109(7):2736-43
pubmed: 17138821
J Clin Oncol. 1998 Aug;16(8):2780-95
pubmed: 9704731
Blood. 2004 Nov 15;104(10):3009-20
pubmed: 15265787

Auteurs

Khalil Saleh (K)

Département d'Hématologie, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94810, Villejuif, France.

Jean-Marie Michot (JM)

DITEP, Institut de Cancérologie Gustave Roussy, Villejuif, France.

Valérie Camara-Clayette (V)

Plateforme AMMICA, Recherche Translationnelle Hématologie, INSERM US23/CNRS UMS3655, Gustave Roussy, Université Paris Sud, Institut de Cancérologie Gustave Roussy, Villejuif, France.

Yegor Vassetsky (Y)

Centre National de la Recherche Scientifique (CNRS) UMR 9018, Université Paris Sud, Institut de Cancérologie Gustave Roussy, Villejuif, France.

Vincent Ribrag (V)

Département d'Hématologie, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94810, Villejuif, France. vincent.ribrag@gustaveroussy.fr.
DITEP, Institut de Cancérologie Gustave Roussy, Villejuif, France. vincent.ribrag@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH